Embecta (NASDAQ: EMBC) revenue
Embecta reported revenue of $1,080m for fiscal 2025, 3.8% less than in fiscal 2024 ($1,123m). Since fiscal 2021 its revenue has fallen by 7.3%, an average decline of 1.9% a year.
Embecta's best year of the last 5 was fiscal 2021. The biggest drop was in fiscal 2025, −3.8%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $1,080m | −3.8% | $242.1m | 22.4% |
| 2024 | $1,123m | +0.2% | $166.8m | 14.9% |
| 2023 | $1,121m | −0.8% | $221.5m | 19.8% |
| 2022 | $1,130m | −3.1% | $309.6m | 27.4% |
| 2021 | $1,165m | — | $492.0m | 42.2% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Embecta revenue compared with its sector
By revenue for its latest fiscal year, Embecta ranks 146th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Embecta, −3.8%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 144th | Waystar | $1,099m | 16.5% |
| 145th | Prestige Consumer Healthcare | $1,089m | −4.3% |
| 146th | Embecta | $1,080m | −3.8% |
| 147th | Acadia Pharmaceuticals | $1,072m | 11.9% |
| 148th | Tandem Diabetes Care | $1,015m | 7.9% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Embecta
- How much revenue did Embecta make in fiscal 2025?
- Embecta reported revenue of $1,080m for fiscal 2025, compared with $1,123m in fiscal 2024.
- How much has the revenue of Embecta fallen?
- Between fiscal 2021 and fiscal 2025 it went from $1,165m to $1,080m: 7.3% less, an average decline of 1.9% a year.
- What was the best year for revenue at Embecta?
- Of its last 5 fiscal years, fiscal 2021, with $1,165m.
- Where does Embecta rank in its sector by revenue?
- It ranks 146th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Embecta come from?
- From the annual report (Form 10-K) that Embecta files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Embecta files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Embecta: the Embecta page · annual accounts · net income · dividends paid · insider transactions.
Dividend per share of Embecta by fiscal year, with the filing behind every figure: Embecta dividend history.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.